ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has submitted an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE). The tumor immunotherapy-focused biotech company boasts a comprehensive product pipeline of over 10 drug candidates targeting innate and adaptive immune checkpoints. Five candidates are currently the focus of seven separate clinical studies in China and the US, with three more being prepared for investigational new drug (IND) applications.
Product Pipeline and Core Product
The firm’s core product is IMM01, an antibody against the cluster of differentiation 47 (CD47) protein. IMM01 is the first SIRPα-Fc fusion protein to enter clinical trials in China and is being developed to treat both blood tumors and solid tumors, either as a monotherapy or in combination with other drugs.
Research and Development Investment
In 2021, ImmuneOnco Biopharmaceuticals invested RMB 176 million (USD 26.3 million) in research and development, underscoring its commitment to advancing its innovative pipeline of immunotherapy candidates.-Fineline Info & Tech
